Whitehawk Therapeutics (WHWK) Capital Expenditures (2016 - 2025)
Whitehawk Therapeutics (WHWK) reported Capital Expenditures of $552000.0 for Q4 2025, up 275.24% year-over-year from $147106.6 in Q4 2024, and up 200.18% on a QoQ basis from -$551000.0 in Q2 2025.
Whitehawk Therapeutics (WHWK) has 9 years of Capital Expenditures data on file, last reported at $552000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 275.24% year-over-year to $552000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1000.0 (down 99.9% YoY) and the FY2025 annual result came in at $552000.0, down 52.12% from the prior year.
- Capital Expenditures improved to $552000.0 in Q4 2025 per WHWK's latest filing, from -$551000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.8 million in Q4 2023 and bottomed at -$1.9 million in Q3 2023.
- The 4-year median for Capital Expenditures is $315000.0 (2022), against an average of $408066.7.
- Peak annual rise in Capital Expenditures reached 5867.86% in 2023, while the deepest fall reached 714.6% in 2023.
- Tracing WHWK's Capital Expenditures over 4 years: stood at $78000.0 in 2022, then surged by 4835.9% to $3.8 million in 2023, then slumped by 108.18% to -$315000.0 in 2024, then soared by 275.24% to $552000.0 in 2025.
- Per Business Quant, the three latest WHWK Capital Expenditures figures stand at $552000.0 (Q4 2025), -$551000.0 (Q2 2025), and $551000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 552,000.00 |
| Dec 31, 2025 | 552,000.00 |
| Jun 30, 2025 | -551,000.00 |
| Jun 30, 2025 | -551,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Dec 31, 2024 | -315,000.00 |
| Dec 31, 2024 | -315,000.00 |
| Sep 30, 2024 | 877,000.00 |
| Sep 30, 2024 | 877,000.00 |
| Jun 30, 2024 | -148,000.00 |
| Jun 30, 2024 | -148,000.00 |
| Mar 31, 2024 | 739,000.00 |
| Mar 31, 2024 | 739,000.00 |
| Dec 31, 2023 | 3.85 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 387,000.00 |
| Mar 31, 2023 | 387,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Dec 31, 2022 | 78,000.00 |
| Sep 30, 2022 | 315,000.00 |
| Sep 30, 2022 | 315,000.00 |
| Jun 30, 2022 | 28,000.00 |
| Jun 30, 2022 | 28,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Sep 30, 2020 | 6,827.00 |
| Sep 30, 2020 | 6,827.00 |
| Dec 31, 2019 | -1.00 |
| Dec 31, 2019 | -1.00 |
| Sep 30, 2019 | 4,281.00 |
| Sep 30, 2019 | 4,281.00 |
| Jun 30, 2019 | 119,389.00 |
| Jun 30, 2019 | 119,389.00 |
| Mar 31, 2019 | 113,283.00 |
| Mar 31, 2019 | 113,283.00 |
| Dec 31, 2018 | 8,532.00 |
| Dec 31, 2018 | 8,532.00 |
| Sep 30, 2018 | 20,882.00 |
| Sep 30, 2018 | 20,882.00 |
| Mar 31, 2018 | 8,498.00 |
| Mar 31, 2018 | 8,498.00 |
| Dec 31, 2017 | 2,349.00 |
| Dec 31, 2017 | 2,349.00 |
| Jun 30, 2017 | 4,339.00 |
| Jun 30, 2017 | 4,339.00 |
| Mar 31, 2017 | 2,208.00 |
| Mar 31, 2017 | 2,208.00 |
| Jun 30, 2016 | 2,848.00 |
| Jun 30, 2016 | 2,848.00 |
| Mar 31, 2016 | 110,449.00 |
| Mar 31, 2016 | 110,449.00 |